ArticleScientific reports2026
Structural diversity and chemical space analysis of a PROTAC database using unsupervised machine learning.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted protein degradation (TPD) mediated by proteolysis-targeting chimeras (PROTACs) has emerged as a powerful therapeutic strategy, enabling the catalytic and selective elimination of disease-relevant proteins via the ubiquitin-proteasome system. Despite their ability to overcome drug resistance and address traditionally undruggable targets, the structural complexity and vast chemical diversity of PROTACs present challenges for systematic analysis and rational design. Here, we present a systematic unsupervised machine-learning framework that represents the first large-scale similarity-driven clustering and scaffold-centric analysis of the PROTAC chemical space, to comprehensively characterize the structural, functional, and physicochemical landscape of PROTAC molecules and to support data-driven lead optimization and next-generation degrader design. An initial dataset of 9,380 compounds was curated from the publicly available PROTACs Database (PROTAC-DB 3.0), followed by rigorous standardization and filtering, resulting in 6,113 unique, chemically valid compounds. The chemical space was explored using a multi-step computational pipeline involving dimensionality reduction and a comparative evaluation of diverse clustering algorithms. Among the evaluated approaches, a refined clustering strategy demonstrated superior performance in partitioning the dataset into structurally coherent groups. Structural analysis revealed a pronounced convergence around canonical PROTAC architectures, characterized by conserved E3 ligase-binding motifs, diverse target-binding frameworks, and heterogeneous linker designs. Functional group profiling and physicochemical analysis further demonstrated that these compounds predominantly occupy a specialized chemical space beyond traditional drug-like limits, marked by high molecular weight and substantial conformational flexibility. Collectively, these findings provide data-driven design guidance for PROTAC optimization by highlighting frequent scaffold architectures and preferred property ranges, thereby informing the development of next-generation degraders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.